Status:

TERMINATED

Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)

Lead Sponsor:

FibroGen

Conditions:

Focal Segmental Glomerulosclerosis

Eligibility:

All Genders

12-64 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of FG-3019 administered over 8 weeks to adolescent and adult subjects with steroid-resistant focal segmental glomerulosclerosis (FS...

Eligibility Criteria

Inclusion

  • Age 12-64 years, inclusive, and girls age 10-11 years, inclusive if Tanner stage 3 or greater
  • Biopsy diagnosis of primary FSGS with biopsy confirmed centrally
  • Age less than or equal to 2 years old at onset of proteinuria
  • First morning urine protein/creatinine ratio (U p/c) \>1 gm/gm
  • Estimated glomerular filtration rate greater than or equal to 40 mL/min/1.73 m2

Exclusion

  • Non-FSGS renal disease other than benign cyst; or secondary FSGS
  • History of organ transplantation
  • History of allergic or anaphylactic reaction to human, humanized, chimeric or murine monoclonal antibodies
  • History of malignancy, cardiovascular disease, diabetes mellitus, sickle cell disease, multiple sclerosis, systemic lupus erythematosus, or active or recurrent serious infections (including but not limited to Hepatitis B, Hepatitis C, or HIV)
  • Participation in studies of investigational drugs within 6 weeks prior to Day 0 or receipt of an investigational drug within 12 weeks prior to Day 0
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2.5 times the upper limit of normal
  • Hematocrit \< 30%

Key Trial Info

Start Date :

April 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 18 2009

Estimated Enrollment :

2 Patients enrolled

Trial Details

Trial ID

NCT00782561

Start Date

April 1 2008

End Date

June 18 2009

Last Update

July 31 2019

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

New Hyde Park, New York, United States, 11040

2

Chapel Hill, North Carolina, United States, 27599-7155

3

Columbus, Ohio, United States, 43205